Acurx Pharmaceuticals, Inc. (ACXP)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 524,210 | |||
| General and administrative | 1,745,473 | |||
| Total operating expenses | 2,269,683 | |||
| Operating loss | -2,269,683 | |||
| Interest income | 23,404 | |||
| Net loss | -2,246,279 | |||
| Earnings per share, basic | -1.89 | |||
| Earnings per share, diluted | -1.89 | |||
| Weighted average number of shares outstanding, basic | 1,190,266 | |||
| Weighted average number of shares outstanding, diluted | 1,190,266 | |||